Analysts Offer Predictions for Q32 Bio FY2029 Earnings

Q32 Bio Inc. (NASDAQ:QTTB) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Q32 Bio in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($0.75) per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share.

Several other equities research analysts also recently commented on QTTB. Raymond James reaffirmed an “outperform” rating and set a $22.00 target price (down from $90.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $16.00 target price (down from $95.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and set a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Oppenheimer reduced their price target on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Finally, Guggenheim cut shares of Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.86.

Q32 Bio Stock Performance

QTTB opened at $3.15 on Friday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. The firm has a market cap of $38.37 million, a PE ratio of -0.22 and a beta of -0.32. The business has a fifty day simple moving average of $6.86 and a 200-day simple moving average of $29.27. Q32 Bio has a fifty-two week low of $2.90 and a fifty-two week high of $53.79.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QTTB. Point72 Asset Management L.P. acquired a new stake in shares of Q32 Bio during the 3rd quarter valued at $3,422,000. FMR LLC raised its holdings in shares of Q32 Bio by 137.3% during the third quarter. FMR LLC now owns 426,302 shares of the company’s stock worth $19,022,000 after acquiring an additional 246,664 shares in the last quarter. Barclays PLC boosted its position in Q32 Bio by 105.2% during the third quarter. Barclays PLC now owns 10,443 shares of the company’s stock valued at $465,000 after purchasing an additional 5,353 shares during the last quarter. Geode Capital Management LLC grew its stake in Q32 Bio by 22.4% in the third quarter. Geode Capital Management LLC now owns 131,768 shares of the company’s stock valued at $5,881,000 after purchasing an additional 24,114 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Q32 Bio during the 3rd quarter worth about $225,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.